GlassScriptPhysician profile
Mohan M Chilukuri
NPI 1407951882
$13,442.34
in general payments reported to CMS, 2019-2025
41 companies · $1,147 in 2025
The $1,147 reported for 2025 was more than what 88% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,624 · 2020: $533 · 2021: $555 · 2022: $839 · 2023: $894 · 2024: $851 · 2025: $1,147.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,892.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,892.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $7,657.85 | 2019 | |
| Novo Nordisk INC | $1,138.85 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $821.60 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $541.85 | 2019-2025 | Jardiance, Synjardy |
| Abbott Laboratories | $530.73 | 2022-2025 | Freestyle Libre 3 |
| Astrazeneca Pharmaceuticals LP | $485.56 | 2019-2024 | Breztri, Airsupra, Farxiga |
| Abbvie INC. | $385.23 | 2020-2025 | Vraylar |
| Pfizer INC. | $339.02 | 2019-2025 | |
| Amgen INC. | $220.22 | 2019-2025 | Repatha |
| Janssen Pharmaceuticals, INC | $146.57 | 2019-2024 | Spravato |
| Lundbeck LLC | $137.99 | 2025 | Rexulti |
| Glaxosmithkline, LLC. | $119.49 | 2020-2023 | Shingrix, Arexvy |
| E.R. Squibb & Sons, L.L.C. | $100.66 | 2019-2025 | Eliquis, Cobenfy |
| Merck Sharp & Dohme LLC | $83.60 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Biohaven Pharmaceutical Holding Company LTD. | $55.95 | 2022 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohan Chilukuri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.